Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer

Featuring a roundtable discussion on the current and future role of PARP inhibitor-based therapy in the management of prostate cancer, with Drs Neeraj Agarwal, Emmanuel Antonarakis, Susan Slovin, and Prof Karim Fizazi, moderated by Dr Neil Love.

Om avsnittet

Fler avsnitt

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Prostate Cancer — The Optimal Use of Hormonal Therapy

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium